ページ11 - イスラエルの最高医師 — オンライン診察を受ける

Head of the Pediatric Neurosurgery Department

アヴラハム・ロルバー博士は、ランバムメディカルセンターの小児科、心臓科、および小児心臓科の専門医であり、英語とヘブライ語を話し、イスラエル工科大学テクニオンのラパポート医学部で上級講師を務め、テルアビブ大学のサックラー医学部を卒業しています。

• 専門分野: 小児科、心臓科、小児心臓科
• 言語: 英語、ヘブライ語
• イスラエル工科大学テクニオンのラパポート医学部で上級講師
• テルアビブ大学のサックラー医学部出身
• 臨床および学術的な関心分野には、先天性/構造的心疾患の診断および介入治療が含まれます
• 臨床活動は、ランバム医療キャンパスのメイヤー小児病院での先天性および後天性心疾患の治療をサポートします

Dr. Vadim Blaustein is a Physics Medicine and Rehabilitation Specialist at Loewenstein Hospital, with expertise in Urodynamic tests:

• Senior Physician and Assistant Manager of the Spinal Rehabilitation Department
• Manages the Unit since 1993
• Professionally cooperates with a nurse

この医師は、Loewenstein Hospital Rehabilitation Centerで神経学とリハビリテーション医学に焦点を当てた経験豊富で高い資格を持つ専門家です。彼女は両分野での認定を受けており、神経学およびリハビリテーション関連の状態の治療を強調しています。彼女の臨床実践は、質の高いケアとサポートを提供し、患者が可能な限り最高の結果を達成するのを助けることに専念しています。<\/p>

Oncologist. Specialist in Medical Oncology and Radiotherapy

この医師は、イスラエルのペタク・ティクヴァにあるRabin Medical Centerで高く評価されている医療専門家です。乳がんを専門とし、HER-2陽性乳がん、トリプルネガティブ乳がん、ホルモン補充療法（HRT）、卵巣摘出術において広範な専門知識を持っています。この医師は、6つの医療状態における卓越性で認識されており、乳がん治療の進歩に対する強い臨床的焦点とコミットメントを示しています。

.

ラファエル・ヒルシュは、30年以上の経験を持つ著名な心臓専門医であり、最も困難な臨床ケースの解決に豊富な知識と経験を持っています。彼の主な実績には次のようなものがあります：

• 先天性心疾患の治療を専門とするサービスの担当者
• 革新的な技術と方法論を用いた複雑な手術の遂行
• エイゼンメンゲル症候群と妊娠中の複雑な心疾患に焦点を当てた研究
• 成人患者の心疾患に特化したサービスの責任者
• イスラエル心臓学会のメンバーおよび先天性心疾患に関する作業グループの創設者
• 科学記事および出版物の著者
• 国際会議およびイスラエル会議のメンバー

アリー・コリツキーは、イスラエルの主要な病院の一つである神経学部の副部長であり、病気の診断および治療のための新しい効果的な方法の研究開発、片頭痛と心臓の働きの間の関係を研究し、自律神経系の機能不全と偏頭痛の治療のための頭痛治療薬の開発と研究を専門としています。

• 神経学部の副部長
• 病気の診断および治療の新しい効果的方法の研究開発
• 片頭痛と心臓の働きの間の関係の研究
• 頭痛治療薬の開発と研究、自律神経系の機能不全と偏頭痛の治療のため

ヴィクトリア・ネイマン博士は、25年の専門的経験と広範な国際経験を持つ著名な腫瘍科専門医、乳腺学者、腫瘍泌尿科医です。以下は、彼女に関する主要なポイントです：

• 泌尿器科悪性腫瘍、乳がん、腫瘍泌尿科、化学療法の治療を専門としています
• イスラエル、ペタHティクヴァのラビン医学センター（イツハク・ラビン医学センター）で腫瘍外科部門を率いています
• 腎臓、膀胱、乳房、精巣、前立腺の急性腫瘍病を持つ患者を治療しています
• がんと放射線治療に関する多くの国内および国際協会のメンバーです
• 多くの国際腫瘍学フォーラムで講演者および参加者を務め、腫瘍泌尿科の分野で多くの臨床実験研究の責任者を務めています

Core Specializations

Oncology:

Head and neck tumors

Thyroid cancer

Personalized biological and immunotherapy

Treatment of recurrent cancer and spinal metastases

Radiotherapy

Education

1998 — Graduated from the Faculty of Medicine at the Hebrew University (Jerusalem, Israel).
2016 — Six-month advanced training course in radiosurgery with a special focus on modern methods of focused radiotherapy for spinal and malignant thyroid tumors at Memorial Sloan Kettering Cancer Center (New York, USA).

Professional Experience

1998–1999 — Internship at Hadassah University Hospital (Jerusalem, Israel).
1999–2005 — Specialization in the Department of Otolaryngology and Head & Neck Surgery at Rabin Medical Center (Petah Tikva, Israel).
2005–2009 — Specialization in oncology and radiotherapy at the Davidoff Cancer Center (Rabin Medical Center).
2006–2008 — Fellowship at the University of Michigan (Ann Arbor, USA) in multidisciplinary cancer treatment.
2008 — Fellowship in head and neck tumor brachytherapy at Beth Israel Medical Center (New York, USA).
2009–2012 — Head of the Head and Neck Oncology Clinic at the Davidoff Cancer Center.
2013–2019 — Chief of the Head and Neck Oncology Division and Deputy Head of the Radiotherapy Department at the Davidoff Cancer Center.
Since 2019 — Director of the Oncology Department and Sharett Cancer Institute at Hadassah University Hospital.

イツハク・ラビン医療センターの心臓病学部門の上級心臓専門医で、リポトミーサービスの責任者。

マガール博士の関心分野：

• 心筋梗塞
• 冠動脈疾患
• コレステロール
• ホモシステイン
• 心筋炎
• 航空医学

アビブ・マガールは定期的に臨床スキルを向上させています。サクラー医科大学に加えて、彼は航空医学のコースを修了し、核心臓学部での研修を終えています。

実践活動に加え、彼は心筋梗塞、ホモシステイン、その他の心臓病の発症リスク要因に関する科学研究と開発に多くの時間を費やしています。

RESEARCH ACTIVITY

1998–2000 — Conducted research on the genesis of cancer at The Royal Marsden Hospital (England).

PUBLICATIONS

Authored numerous peer-reviewed articles in scientific journals. Selected topics include:

Oncotype Dx Recurrence Score in BRCA1/2 germline mutation carriers with hormone receptor-positive breast cancer.

TP53 missense mutation recurrence in cancer patients of Arab descent.

Adjuvant autologous vaccine for stage III microscopic melanoma: biomarker survival and enhanced response to CTLA-4 blockade.

Prognostic significance of (R)CA15-3 assay in primary breast cancer.

Diagnostic and prognostic value of comparative thymidine kinase 1 (TK1) activity assays in breast cancer patient serum.

Complete remission in a BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma treated with cisplatin.

Autologous vaccine-induced antitumor and self-reactive immune responses in melanoma: impact on patient survival and dependence on MHC class II expression.

PROFESSIONAL AFFILIATIONS

Israeli Society of Clinical Oncology

Israel Medical Association

AWARDS & GRANTS

Cancer Genetics Research Foundation Award

Landau Prize

Judith Segal Memorial Award

Liver transplant surgeon

Obstetrics and Gynecology specialist

Gynecologist, Specialist in Endoscopic Surgery

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Prof. Gil Raviv, MD, PhD, is Director of the Andrology Unit at Sheba Medical Center. He was listed among the Best Doctors in Israel by Forbes in 2024. He is a leading expert in male fertility, sexual medicine, and reconstructive urology.

His primary focus is male infertility and fertility preservation. He performs advanced semen analysis according to WHO standards. He carries out testicular sperm retrieval (TESE, TESA, MESA) and semen cryopreservation. He also provides comprehensive fertility diagnostics with histological analysis.

He is a Professor at Tel Aviv University. He trained in Siena, Rome, and Tel Aviv. He completed a fellowship in infertility and impotence at Erasme Hospital. He received advanced training in reconstructive urethral surgery in Ghent. He is a member of the European Association of Urology, the International Society for Sexual Medicine, and the Israeli Urological Association.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.